Century Therapeutics, Inc. (IPSC)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Century Therapeutics, Inc. reported revenue of $109.16M, up 1556.8% from the prior year. The company ran a net loss, with a net margin of -8.8%. It held $223.70M in total assets against $64.77M in total liabilities.
Key ratios (FY2025)
-15.8%
Operating margin
-8.8%
Net margin
-6.0%
Return on equity
+1556.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $109.16M | $6.59M | $2.23M | $5.20M | — | — | — |
| Operating Income | -$17.27M | -$138.14M | -$146.55M | -$133.83M | -$94.88M | -$53.90M | — |
| Net Income | -$9.58M | -$126.57M | -$136.67M | -$130.93M | -$95.82M | -$53.58M | — |
| EPS (Diluted) | $-0.14 | $-1.61 | $-2.30 | $-2.96 | $-2.96 | $-7.16 | — |
| Total Assets | $223.70M | $353.22M | $360.69M | $486.54M | $437.38M | $106.78M | — |
| Total Liabilities | $64.77M | $191.85M | $175.94M | $183.81M | $41.14M | $33.43M | — |
| Shareholders' Equity | $158.94M | $161.36M | $184.75M | $302.74M | $396.24M | -$106.41M | -$91.86M |
| Cash & Equivalents | $61.85M | $58.44M | $47.32M | $84.27M | $56.45M | $27.21M | — |
| Operating Cash Flow | -$103.88M | -$110.14M | -$88.35M | $14.05M | -$89.00M | -$41.27M | — |
| Capital Expenditures | $848.0K | $154.0K | $13.74M | $30.60M | $44.97M | $9.82M | — |
| Shares Outstanding | 87.52M | 85.84M | 60.34M | 55.01M | 58.47M | 7.48M | — |